Overall verdict
Neutral
4.0/10
1-year performance
+118.09%
Score breakdown
Up 118.1% over 1 year, 100% of the 52-week range.
Strongest: Growth 9.5/10. Weakest: Profitability 0.0/10.
24 analysts, target -0.1% vs the price.
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer ; Latitude, a blood-based MRD test for colorectal cancer ; Altera, a tissue based comprehensive genomic profiling test ;
and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses ;
Empower, a hereditary cancer screening test ; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation ; Renasight, a kidney gene panel test ; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services.
The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use.
The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Steven Chapman
Founded
2003
Employees
6 140
Revenue / employee
375 588 USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- JPMORGAN CHASE & CO9.42%
- BlackRock, Inc.7.99%
- PRICE T ROWE ASSOCIATES INC /MD/6.61%
- VANGUARD CAPITAL MANAGEMENT LLC4.56%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.24%
- FMR LLC3.99%
- WELLINGTON MANAGEMENT GROUP LLP2.96%
- STATE STREET CORP2.68%
- Duquesne Family Office LLC2.33%
- Other institutions55.41%
843 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
412.93 USD
52-week low
157.43 USD
1-year performance
118.09%
Rising
Year-to-date performance
70.69%
Rising
Drawdown
-0.07%
Near its high
Position in the 52-week range
100% of range
Against the world ETF
Over 11 years, from July 2015 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 4.6 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of July 2015 are worth today
| Natera | 168 812 € |
| World ETF | 32 280 € |
| S&P 500 | 41 456 € |
| Risk-free placement | 10 911 € |
The risk
- Shaking:the share moves 4.6 times as much as the world ETF.
- Worst fall:-75 % between September 2021 and May 2022. 10,000 € placed at the top fell to 2 479 €. The world ETF, at worst: -34 %. Back to its high in 27 months.
Natera earned 5 times as much as the world ETF since 2015
Value of 10,000 euros placed at the end of July 2015, dividends reinvested, in euros
- Natera: 168 812 €
- World ETF: 32 280 €
- S&P 500: 41 456 €
- Risk-free placement: 10 911 €
Based on past performance. This is not a recommendation.
Gross margin 64.7%, the company loses 7.1% of its revenue, ROIC -11.6%, ROE -12.5%.
Net margin
-7.11%
Negative
Sector -15.62%|S&P 12.97%
Gross margin
64.74%
Fair
Return on equity (ROE)
-12.54%
Negative
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
-11.61%
Negative
Free cash flow margin (FCF)
3.11%
Low
Margin stability
21.2 pts
Very uneven
Revenue to net income
Growth
9.5/10Revenue up 37.7% over 1 year, 42.6% a year over 5.
Revenue (trailing 12 months)
2.7Md USD
Revenue growth (1y)
37.71%
Hyper-growth
Revenue growth (3y)
181.16%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 29.6x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 23.3x|S&P 14.5x
PEG
—
Sector 0.12|S&P 0.86
Market cap
56.3Md USD
Financial strength
7.3/10Cash covers 457.7% of the debt, net debt/EBITDA 0.8x.
Net debt / EBITDA
0.8x
Solid
Gearing (net debt / equity)
-46.83%
Net cash
Cash
1.1Md USD
Cash / market cap
1.94%
Stretched
Cash / total debt
457.68%
Net cash
Interest coverage
-75.9x
Stretched
Net debt
-853M USD
Equity
1.8Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 408.79 USD
- MM20346.64
- MM50313.65
- MM200243.69
- RSI 1483.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+5.65%
200-day average slope, 3 months
+17.08%
50-day average slope, 1 month
+13.10%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.45 % per day
Volatility change
-28.40%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.36 (20) | -1.39 (16) | 2 909 (23) | -162 (14) | -192 (18) |
| 2027 | 0.01 (20) | -0.10 (16) | 3 490 (23) | 69 (14) | 11 (17) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 25, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | NTRA | 4.0 | 3.0 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 0.8x | 0.1 % | 118.1 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
